QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANALYSIS OF RETINAL DEGENERATIVE CHANGES IN DIABETIC MACULAR EDEMA AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina. 2018 Jul;38(7):1324-1330. doi: 10.1097/IAE.0000000000001696.

Abstract

Purpose: To investigate the relationship of the pre-anti-vascular endothelial growth factor (VEGF) retinal tissue area (RTA) and optical density (ODRT) of the retinal optical slice portion located in the central subfield, and their ratio (RTA/ODRT), in the presence of diabetic macular edema or of inraretinal cystic fluid in neovascular age-related macular degeneration, to central retinal thickness and best-corrected visual acuity after anti-VEGF treatment with ME resolution.

Methods: The optical coherence tomography images and medical records of 33 patients (41 eyes) with neovascular age-related macular degeneration, 15 (21 eyes) with diabetic macular edema and 9 healthy individuals (15 eyes) were retrospectively analyzed. RTA, ODRT, and RTA/ODRT were calculated on pre-anti-VEGF B-scan images. Spearman rank correlation was used to assess the relationship of central retinal thickness and best-corrected visual acuity after anti-VEGF treatment with the variables under study.

Results: Pre-anti-VEGF RTA was positively correlated with post-anti-VEGF central retinal thickness (ρ = 0.76; P < 0.001) and best-corrected visual acuity (ρ = 0.67; P < 0.001), whereas pre-anti-VEGF ODRT was moderately negatively correlated (ρ = -0.26; P = 0.049 and ρ = -0.48; P = 0.001, respectively) and pre-anti-VEGF RTA/ODRT ratio was strongly positively correlated (ρ = 0.75; P < 0.001 and ρ = 0.85; P < 0.001, respectively). The area under curve for RTA/ODRT ratio was 0.93 (P < 0.001), and the cut-off value for post-anti-VEGF LogMAR best-corrected visual acuity of 0.4 (20/50 Snellen equivalent) or worse was 1,406.7 μm/U (sensitivity: 0.94; specificity: 0.78).

Conclusion: Both RTA and ODRT, or, preferably, RTA/ODRT ratio alone can be used as predictors of functional and anatomic outcomes in patients with diabetic macular edema or neovascular age-related macular degeneration treated with anti-VEGF therapy.

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / administration & dosage
  • Diabetic Retinopathy / complications*
  • Diabetic Retinopathy / diagnosis
  • Diabetic Retinopathy / drug therapy
  • Female
  • Humans
  • Intravitreal Injections
  • Macula Lutea / pathology*
  • Macular Edema / complications*
  • Macular Edema / diagnosis
  • Macular Edema / drug therapy
  • Male
  • Middle Aged
  • Ranibizumab / administration & dosage
  • Retinal Degeneration / diagnosis*
  • Retinal Degeneration / drug therapy
  • Retinal Degeneration / etiology
  • Retrospective Studies
  • Tomography, Optical Coherence / methods*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity
  • Wet Macular Degeneration / complications*
  • Wet Macular Degeneration / diagnosis
  • Wet Macular Degeneration / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A
  • Ranibizumab